123,293 Shares in Humana Inc. (NYSE:HUM) Bought by SRS Investment Management LLC

SRS Investment Management LLC purchased a new position in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 123,293 shares of the insurance provider's stock, valued at approximately $31,281,000. Humana comprises 0.4% of SRS Investment Management LLC's investment portfolio, making the stock its 17th largest position. SRS Investment Management LLC owned about 0.10% of Humana at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter worth $27,000. Centricity Wealth Management LLC purchased a new stake in Humana in the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA grew its holdings in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after acquiring an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new position in Humana during the 4th quarter valued at about $33,000. Finally, Transce3nd LLC bought a new stake in shares of Humana in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analyst Ratings Changes

HUM has been the topic of several research reports. Royal Bank of Canada reissued an "outperform" rating and set a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Morgan Stanley cut their price target on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 12th. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 15th. Robert W. Baird lifted their target price on Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Humana currently has an average rating of "Hold" and an average target price of $284.90.

Humana Stock Performance

NYSE HUM traded down $3.91 during trading hours on Friday, reaching $263.92. The stock had a trading volume of 1,097,942 shares, compared to its average volume of 1,745,084. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The stock has a market cap of $31.85 billion, a P/E ratio of 26.52, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The stock has a fifty day moving average of $266.22 and a 200 day moving average of $270.36.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is presently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.